DFV890: a new oral NLRP3 inhibitor—tested in an early phase 2a randomised clinical trial in patients with COVID-19 pneumonia and impaired respiratory function

Ildikó Madurka, Alexander Vishnevsky, Joan B. Soriano, Stephanus J. Gans, Danilo Joel Salazar Ore, Adrián Rendón, Charlotte Suppli Ulrik, Sushma Bhatnagar, Srikanth V. Krishnamurthy, Kirsten Mc Harry,

Infection · 2022 · 83 citations · 19 references

DOIFull text

Open access

Concepts

References

19